Cyclin D1 anticorps

N° du produit ABIN7127907

Détail du produit anti-Cyclin D1 anticorps

Antigène: Cyclin D1 (CCND1)

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Cyclin D1 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunocytochemistry (ICC)

Réactivité croisée: Humain, Souris, Rat

Purification: Affinity purification

Immunogène: A synthetic peptide of Human Cyclin D1

Isotype: IgG

Information d'application

Indications d'application: WB:1:500-1:1000, IHC:1:50-1:100, ICC:1:50-1:100, IP:1:20-1:50,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Store at -20 °C or -80 °C. Avoid freeze / thaw cycles. Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur Cyclin D1

Antigène: Cyclin D1 (CCND1)

Autre désignation: CCND1 (CCND1 Produits)

Synonymes: anticorps BCL1, anticorps D11S287E, anticorps PRAD1, anticorps U21B31, anticorps AI327039, anticorps CycD1, anticorps Cyl-1, anticorps bcl-1, anticorps cD1, anticorps cb161, anticorps cycd1, anticorps etID37810.7, anticorps fb52e01, anticorps fc45c08, anticorps fc83a12, anticorps id:ibd1198, anticorps wu:fb52e01, anticorps wu:fc45c08, anticorps wu:fc83a12, anticorps ccnd1b, anticorps prad1, anticorps ccnd1, anticorps ccnd1a, anticorps bcl1, anticorps d11s287e, anticorps u21b31, anticorps CCND1, anticorps cyclin D1, anticorps cyclin D1 S homeolog, anticorps cyclin D1 L homeolog, anticorps CCND1, anticorps Ccnd1, anticorps ccnd1, anticorps ccnd1.S, anticorps ccnd1.L

Sujet:

Background: Activity of the cyclin-dependent kinases CDK4 and CDK6 is regulated by T-loop phosphorylation, by the abundance of their cyclin partners (the D-type cyclins), and by association with CDK inhibitors of the Cip/Kip or INK family of proteins. The inactive ternary complex of cyclin D/CDK4 and p27 Kip1 requires extracellular mitogenic stimuli for the release and degradation of p27 concomitant with a rise in cyclin D levels to effect progression through the restriction point and pRb-dependent entry into S-phase. The active complex of cyclin D/CDK4 targets the retinoblastoma protein for phosphorylation, allowing the release of E2F transcription factors that activate G1/S-phase gene expression. Levels of cyclin D protein drop upon withdrawal of growth factors through downregulation of its protein expression and through phosphorylation-dependent degradation.

Aliases: AI327039 antibody, B cell CLL/lymphoma 1 antibody, B cell leukemia 1 antibody, B cell lymphoma 1 protein antibody, B-cell lymphoma 1 protein antibody, BCL 1 antibody, BCL-1 antibody, BCL-1 oncogene antibody, BCL1 antibody, BCL1 oncogene antibody, ccnd1 antibody, CCND1/FSTL3 fusion gene antibody, CCND1/FSTL3 fusion gene, included antibody, CCND1/IGHG1 fusion gene antibody, CCND1/IGHG1 fusion gene, included antibody, CCND1/IGLC1 fusion gene antibody, CCND1/IGLC1 fusion gene, included antibody, CCND1/PTH fusion gene antibody, CCND1/PTH fusion gene, included antibody, CCND1_HUMAN antibody, cD1 antibody, Cyl 1 antibody, D11S287E antibody, G1/S specific cyclin D1 antibody, G1/S-specific cyclin-D1 antibody, Parathyroid adenomatosis 1 antibody, PRAD1 antibody, PRAD1 oncogene antibody, U21B31 antibody

UniProt: P24385

Pathways: Signalisation PI3K-Akt, Cycle Cellulaire, Mitotic G1-G1/S Phases, ER-Nucleus Signaling